Shanghai/Suzhou, China, 30th December 2020. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, was named as one of the Cultivated Unicorn Enterprises of Suzhou, which testified that Elpiscienece’s leadership has gained recognition over the industry.
Elpiscience is a clinical stage biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the innovation and development of the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpiscience has a pipeline of more than 10 innovative molecules in discovery, covering a wide range of targets with a particular focus on innate immunity and tumor microenvironment.Its most advanced assets, ES101 and ES102 are both in Phase I clinical stage, and three in-house developed candidates with first-in-class potential are currently being evaluated in IND-enabling studies. Elpiscience’s sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies.